ClinicalTrials.gg
CompletedNCT05959447Updated Mar 26, 2025Results posted

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

A Phase 1 interventional study of Camlipixant and Dabigatran etexilate in Cough and Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.

Enrollment
5th of 10
45 · median 44
Started
2023
with 1 other
Phase 1
7 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
Bellus Health Inc. - a GSK company

Among the 10 studies testing BLU-5937 in Cough, this one is the 5th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 6th registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About BLU-5937

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing BLU-5937 in Cough, or all of them as a file.
02

Study summary

This is a phase 1, 2-part, open-label, fixed-sequence study evaluating potential drug-drug interactions between gemfibrozil (part 1) or dabigatran etexilate (part 2) and camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

03

Conditions studied

  • Cough
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females

Exclusion criteria

Exclusion Criteria:

  • History of history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disorder, as judged by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg

    Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.

    Drug: Camlipixant · Drug: Gemfibrozil

  • Experimental
    Part 2: Dabigatran etexilate 150 mg + camlipixant 50 mg

    Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1, followed by repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. There was a washout of at least 4 days between the dose of dabigatran etexilate on Day 1 and the dose of camlipixant on Day 5.

    Drug: Camlipixant · Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  2. Part 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  3. Part 1: Maximal Observed Concentration (Cmax) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  4. Part 2: AUC(0-Infinity) of Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  5. Part 2: AUC(0-t) of Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  6. Part 2: Cmax of Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  7. Part 2: AUC(0-Infinity) of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  8. Part 2: AUC(0-t) of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  9. Part 2: Cmax of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Secondary outcomes

  1. Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  2. Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  3. Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  4. Part 1: Terminal Elimination Rate Constant of Camlipixant (Kel)

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  5. Part 1: Apparent Clearance (CL/F) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  6. Part 1: Apparent Volume of Distribution (Vz/F) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

  7. Part 2: Tmax of Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  8. Part 2: T1/2 Following Administration Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  9. Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  10. Part 2: Kel Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  11. Part 2: CL/F Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  12. Part 2: Vz/F Free Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  13. Part 2: Tmax of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  14. Part 2: T1/2 Following Administration of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  15. Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  16. Part 2: Kel of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  17. Part 2: CL/F of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  18. Part 2: Vz/F of Total Dabigatran

    Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

  19. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration

    Time frame: Day 1 post-dose until Day 5 pre-dose of gemfibrozil [camlipixant 50mg]; from Day 5 dosing until Day 9 pre-dose of camlipixant [gemfibrozil 600mg]; from camlipixant dosing on Day 9 until end of study [Day 21] [camlipixant 50mg+gemfibrozil 600mg]

  20. Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs

    An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to: taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

    Time frame: Day1 postdose until Day5 predose of camlipixant [dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran [camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day 22][dabigatran etexilate 150mg+camlipixant 50mg]

  21. Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings

    A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

    Time frame: Day 5, Day 9 pre-dose and 1 hour post-dose, Day 12

  22. Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings

    A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

    Time frame: Day 5, Day 10 and Day 13

  23. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate

    Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 9 and Day 12

  24. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate

    Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 10 and Day 13

  25. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

    Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 12

  26. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

    Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 13

  27. Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination

    Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

    Time frame: Up to Day 12

  28. Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination

    Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

    Time frame: Up to Day 13

  29. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

    Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

    Time frame: Up to Day 12

  30. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

    Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

    Time frame: Up to Day 13

  31. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

    Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

    Time frame: Up to Day 12

  32. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

    Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

    Time frame: Up to Day 13

  33. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

    Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

    Time frame: Up to Day 12

  34. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

    Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

    Time frame: Up to Day 13

  35. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

    Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

    Time frame: Up to Day 12

  36. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

    Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

    Time frame: Up to Day 13

07

Results

Posted Mar 26, 2025

Participant flow

Part 1 (Up to Day 21)
Participant flow — Part 1 (Up to Day 21)
MilestonePart 1: Camlipixant 50 mg + Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Started250
Safety population160
Completed150
Not completed100
Withdrew: Adverse event10
Withdrew: Enrolled but did not receive study treatment90
Part 2 (Up to Day 22)
Participant flow — Part 2 (Up to Day 22)
MilestonePart 1: Camlipixant 50 mg + Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Started020
Safety population016
Completed014
Not completed06
Withdrew: Adverse event02
Withdrew: Enrolled but did not receive study treatment04

Outcome measures

PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant
Hours*nanograms per milliliterPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 14886.66 ± 28.69
Day 910642.07 ± 24.17
PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant
Hours*nanograms per milliliterPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 14846.83 ± 28.84
Day 910541.57 ± 24.44
PrimaryPart 1: Maximal Observed Concentration (Cmax) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Nanograms per milliliter
Part 1: Maximal Observed Concentration (Cmax) of Camlipixant
Nanograms per milliliterPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 11078 ± 25.02
Day 91303 ± 25.65
PrimaryPart 2: AUC(0-Infinity) of Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-Infinity) of Free Dabigatran
Hours*nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1943.49 ± 52.12
Day 101055.20 ± 43.81
PrimaryPart 2: AUC(0-t) of Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-t) of Free Dabigatran
Hours*nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1920.18 ± 53.11
Day 101031.89 ± 45.03
PrimaryPart 2: Cmax of Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Nanograms per milliliter
Part 2: Cmax of Free Dabigatran
Nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1110 ± 53.53
Day 10125 ± 47.75
PrimaryPart 2: AUC(0-Infinity) of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-Infinity) of Total Dabigatran
Hours*nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 11165.82 ± 52.34
Day 101339.35 ± 41.21
PrimaryPart 2: AUC(0-t) of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-t) of Total Dabigatran
Hours*nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 11139.80 ± 53.51
Day 101316.80 ± 41.83
PrimaryPart 2: Cmax of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Nanograms per milliliter
Part 2: Cmax of Total Dabigatran
Nanograms per milliliterPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1135 ± 54.20
Day 10160 ± 42.42
SecondaryPart 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Median · Hours
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant
HoursPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 10.750 (0.500 to 2.000)
Day 90.750 (0.500 to 2.500)
SecondaryPart 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Hours
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant
HoursPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 15.56 ± 31.80
Day 99.56 ± 18.60
SecondaryPart 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Percentage of AUC extrapolation
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant
Percentage of AUC extrapolationPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 10.58 ± 104.04
Day 90.59 ± 109.24
SecondaryPart 1: Terminal Elimination Rate Constant of Camlipixant (Kel)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · h^-1
Part 1: Terminal Elimination Rate Constant of Camlipixant (Kel)
h^-1Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 10.1247 ± 31.80
Day 90.0725 ± 18.60
SecondaryPart 1: Apparent Clearance (CL/F) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Liters per hour
Part 1: Apparent Clearance (CL/F) of Camlipixant
Liters per hourPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 110.23 ± 28.69
Day 94.70 ± 24.17
SecondaryPart 1: Apparent Volume of Distribution (Vz/F) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Reported as:
Geometric mean · Liters
Part 1: Apparent Volume of Distribution (Vz/F) of Camlipixant
LitersPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 182.06 ± 22.57
Day 964.80 ± 23.69
SecondaryPart 2: Tmax of Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Median · Hours
Part 2: Tmax of Free Dabigatran
HoursPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 12.000 (1.500 to 3.500)
Day 102.000 (1.500 to 3.000)
SecondaryPart 2: T1/2 Following Administration Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours
Part 2: T1/2 Following Administration Free Dabigatran
HoursPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 110.49 ± 18.23
Day 109.18 ± 9.16
SecondaryPart 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Percentage of AUC extrapolation
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran
Percentage of AUC extrapolationPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 12.22 ± 49.87
Day 101.95 ± 52.63
SecondaryPart 2: Kel Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · h^-1
Part 2: Kel Free Dabigatran
h^-1Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 10.0660 ± 18.23
Day 100.0755 ± 9.16
SecondaryPart 2: CL/F Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters per hour
Part 2: CL/F Free Dabigatran
Liters per hourPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1158.98 ± 52.12
Day 10142.15 ± 43.81
SecondaryPart 2: Vz/F Free Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters
Part 2: Vz/F Free Dabigatran
LitersPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 12407.03 ± 54.73
Day 101883.56 ± 43.72
SecondaryPart 2: Tmax of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Median · Hours
Part 2: Tmax of Total Dabigatran
HoursPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 12.000 (1.000 to 3.500)
Day 102.000 (1.000 to 3.000)
SecondaryPart 2: T1/2 Following Administration of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours
Part 2: T1/2 Following Administration of Total Dabigatran
HoursPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 111.04 ± 30.01
Day 1010.21 ± 16.90
SecondaryPart 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Percentage of AUC extrapolation
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran
Percentage of AUC extrapolationPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 11.93 ± 59.97
Day 101.58 ± 37.14
SecondaryPart 2: Kel of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · h^-1
Part 2: Kel of Total Dabigatran
h^-1Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 10.0628 ± 30.01
Day 100.0679 ± 16.90
SecondaryPart 2: CL/F of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters per hour
Part 2: CL/F of Total Dabigatran
Liters per hourPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 1128.66 ± 52.34
Day 10111.99 ± 41.21
SecondaryPart 2: Vz/F of Total Dabigatran

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters
Part 2: Vz/F of Total Dabigatran
LitersPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 12048.49 ± 61.16
Day 101649.21 ± 37.35
SecondaryPart 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration

Time frame:
Day 1 post-dose until Day 5 pre-dose of gemfibrozil [camlipixant 50mg]; from Day 5 dosing until Day 9 pre-dose of camlipixant [gemfibrozil 600mg]; from camlipixant dosing on Day 9 until end of study [Day 21] [camlipixant 50mg+gemfibrozil 600mg]
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)
ParticipantsPart 1: Camlipixant 50 mgPart 1: Gemfibrozil 600 mgPart 1: Camlipixant 50 mg+ Gemfibrozil 600 mg
TEAEs165
TESAEs001
TEAEMIs001
SecondaryPart 2: Number of Participants With TEAEs, TESAEs and TEAEMIs

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to: taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Time frame:
Day1 postdose until Day5 predose of camlipixant [dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran [camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day 22][dabigatran etexilate 150mg+camlipixant 50mg]
Reported as:
Count of participants · Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs
ParticipantsPart 2: Dabigatran Etexilate 150 mgPart 2: Camlipixant 50 mgPart 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg
TEAEs460
TESAEs000
TEAEMIs000
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Time frame:
Day 5, Day 9 pre-dose and 1 hour post-dose, Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 50
Day 9, Pre-dose0
Day 9,1-Hour Post-dose0
Day 120
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Time frame:
Day 5, Day 10 and Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 50
Day 100
Day 130
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 9 and Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Day 90
Day 120
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 10 and Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Day 100
Day 130
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination1
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters3
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters1
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
ParticipantsPart 1: Camlipixant 50 mg + Gemfibrozil 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
ParticipantsPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis0

Adverse events

Collected over Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Camlipixant 50 mg0/16 (0%)0/16 (0%)1/16 (6.3%)
Part 1: Gemfibrozil 600 mg0/16 (0%)0/16 (0%)6/16 (37.5%)
Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg0/16 (0%)1/16 (6.3%)5/16 (31.3%)
Part 2: Dabigatran Etexilate 150 mg0/16 (0%)0/16 (0%)4/16 (25%)
Part 2: Camlipixant 50 mg0/15 (0%)0/15 (0%)6/15 (40%)
Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg0/14 (0%)0/14 (0%)0/14 (0%)
Most frequent serious events
Most frequent serious events
EventPart 1: Camlipixant 50 mgPart 1: Gemfibrozil 600 mgPart 1: Camlipixant 50 mg+ Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mgPart 2: Camlipixant 50 mgPart 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg
Hepatic enzyme increasedInvestigations0/160/161/160/160/150/14
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPart 1: Camlipixant 50 mgPart 1: Gemfibrozil 600 mgPart 1: Camlipixant 50 mg+ Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mgPart 2: Camlipixant 50 mgPart 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg
Abdominal painGastrointestinal disorders0/161/160/160/162/150/14
HeadacheNervous system disorders0/160/161/161/161/150/14
ConstipationGastrointestinal disorders1/161/160/161/161/150/14
Faeces softGastrointestinal disorders0/161/160/160/161/150/14
Alanine aminotransferase increasedInvestigations0/161/160/160/161/150/14
Aspartate aminotransferase increasedInvestigations0/161/160/160/161/150/14
DiarrhoeaGastrointestinal disorders0/160/160/160/161/150/14
Gamma-glutamyltransferase increasedInvestigations0/160/160/160/161/150/14
Dry eyeEye disorders0/160/160/160/161/150/14
Procedural dizzinessInjury, poisoning and procedural complications0/160/160/160/161/150/14

Baseline characteristics

Baseline characteristics are reported for the Safety Population which consisted of all participants who received at least one dose of any study drug.

Age, Customized
Age, Customized(Participants)Part 1: Camlipixant 50 mg + Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mgTotal
23 to 54 years161632
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Camlipixant 50 mg + Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mgTotal
Female7714
Male9918
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Camlipixant 50 mg + Gemfibrozil 600 mgPart 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mgTotal
All Other Races224
White141428
08

Study locations

1 site
  • GSK Investigational Site
    Quebec City, Quebec G1P 0A2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2023, 2 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion.

Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 25, 2023
StartActual
Jul 26, 2023
Primary completionActual
Oct 13, 2023
CompletionActual
Oct 13, 2023
Results first posted
Mar 26, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05959447
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Jul 26, 2023
Primary completion
Oct 13, 2023
Completion
Oct 13, 2023
Results posted
Mar 26, 2025
Last update
Mar 26, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion